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Abstract
Background A majority of older adults in the United States (US) use prescription medications. Comprehensive population-
level approaches to examine medication safety, effectiveness, and costs among older adults are needed.
Objectives The objectives of this study were to develop a framework of quality measures spanning the domains of safety, effective-
ness, and efficiency of prescription medication use among older adults, and to apply those measures using pharmacy claims data.
Methods We performed a retrospective study among adults age 65 years and older of a US East Coast state who filled at 
least one prescription from a particular pharmacy chain during 2016 (N = 99,056). Firstly, we performed an environmental 
scan to identify quality measures and potentially relevant measures addressing prescription medication use. These measures 
were reviewed and rated by local geriatric pharmacotherapy experts. After evaluating feasibility, evidence, and relevance, 
a total of 19 measures representing the domains of safety (n = 7), effectiveness (n = 7), and efficiency (n = 5) were identi-
fied. These measures were then applied to an older adult population using prescription data for the year 2016 provided by 
a national pharmacy chain. All measures were configured such that a score of 100% corresponded to optimal performance.
Results For the domain of safety, 12.8% of patients received a benzodiazepine chronically, 23.6% received central nervous system 
depressants, 16.7% received fluoroquinolones as first-line antibiotic therapy, and 21.9% of those who were prescribed opioids 
received them in excessive quantities. For the domain of effectiveness, one-fourth of the diabetes patients did not receive statins 
and angiotensin-acting medications, while 18.0% were not adherent to oral anticoagulant medications and 54% were not adherent to 
respiratory inhalers. For the domain of efficiency, 12.0% of the patients received prescriptions from five or more unique prescribers. 
Overall, 85.7%, 76.1%, and 87.9% of the older adults showed safe, effective, and efficient prescription medication use, respectively.
Conclusion A novel approach to comprehensively examine the quality of medication use among older adults using prescrip-
tion claims data is provided in our study. A considerable proportion of the older adults in our study received safe, effective, 
and efficient prescription medications. However, within each domain, several opportunities for improving the alignment of 
prescription medication use with current recommendations were identified.
This project was presented at the Academy of Managed Care 
Pharmacy (AMCP) Managed Care and Specialty Pharmacy 2018 
Annual Meeting, Boston, MA, USA.
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Key Points 
A novel approach/measurement framework to compre-
hensively assess safe, effective, and efficient prescrip-
tion medication use among older adults using pharmacy 
claims data is presented.
Overall, 14%, 24%, and 12% of older adults did not show 
safe, effective, and efficient prescription medication use, 
respectively.
Many opportunities for quality improvement within 
the domains of safety, effectiveness, and efficiency of 
prescription medication use among older adults were 
identified.
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1 Introduction
Most older adults in the United States (US) utilize pre-
scription medication, and approximately 40% are pre-
scribed five or more medications [1]. While medication 
is intended to extend life or improve quality of life, its 
adverse effects can increase morbidity and mortality [2]. 
Conversely, optimal health outcomes are unrealized when 
patients fail to receive or to adhere to their medications. 
Additionally, medication cost is an increasing concern 
confronting patients and the health system. Comprehen-
sive population-level approaches to assess and improve 
medication safety, effectiveness, and efficiency among 
older adults are needed, particularly in the US, where care 
fragmentation and lack of effective care coordination can 
lead to medication misuse and underuse.
Performance measurement is integral to quality improve-
ment. Measures addressing medication use among older 
adults have been developed by several entities. Foremost, 
the Pharmacy Quality Alliance (PQA) has developed a 
range of quality measures of prescription medication utili-
zation, including measures addressing medication safety and 
patient adherence [3]. The US Medicare program provides a 
privately administered prescription drug benefit, and has 
developed a star rating system for evaluating quality among 
drug plan sponsors, using a scheme that includes several of 
the PQA’s measures. Other prominent efforts to evaluate 
the quality of medication use among older adults include 
the Assessing Care of Vulnerable Elders (ACOVE) initia-
tive [4, 5] and the Beers criteria [6]. The ACOVE measures 
assess the quality of medication use across 22 health condi-
tions [4, 5]. The Beers criteria for potentially inappropriate 
medication use in older adults identifies higher-risk medica-
tions that should generally be avoided overall, or avoided or 
dose adjusted among particular patients [6]. Other notable 
efforts include the Medication Appropriateness Index (MAI) 
[7] and the START/STOPP criteria [8].
There are shortcomings to performance measurement. It 
is challenging to scale patient-level approaches to screen 
populations, particularly those that rely upon reviews of 
medication lists or patient interviews. For measures that 
utilize administrative claims data, calculating measure 
rates often requires the integration of pharmacy and medi-
cal databases, and can involve complex measure specifica-
tions. Moreover, given the breadth of medication use across 
the myriad health conditions that are prevalent among older 
adults, it is unlikely that any sole measure will have a dra-
matic impact on population health outcomes.
We envisioned a quality measurement framework 
addressing medication use among older adults, aligned with 
the core domains for health technology assessment of safety, 
effectiveness, and cost (efficiency), comprised of measures 
that can be calculated using pharmacy data solely. While 
pharmacy claims data lack information about medical diag-
noses and procedures, there are many health conditions that 
can be identified with acceptable specificity according to the 
medication prescribed. We sought an approach that would 
simplify the complexity associated with analysis of inte-
grated medical, hospital, pharmacy and eligibility data com-
mon to many performance measures. We sought to identify 
or develop quality measures of medication use among older 
adults derived from pharmacy claims, and to apply these 
measures to determine their suitability for population-level 
analyses. This study presents our S–E–E (Safety–Effective-
ness–Efficiency) measurement framework and describes its 
application using pharmacy data for a population of older 
adults.
2  Methods
The first phase of the two-phase study was to identify or 
develop measures relevant to our purpose; the second phase 
involved applying these measures to calculate results, overall 
and according to patient characteristics.
The process of identifying suitable quality measures 
involved a targeted search of the published literature, 
identifying measures currently used with the US health-
care system, and brainstorming ideas for new measures 
with geriatric pharmacotherapy experts from our institu-
tion. A targeted literature review was performed by query-
ing PubMed using the search terms “Beers,” “ACOVE,” 
and “START/STOPP,” as informed by the authors’ prior 
awareness of these efforts. This search yielded reviews 
of these quality measurement initiatives and other efforts 
described in their reference lists that were then exam-
ined for their relevance to older adults and applicabil-
ity to pharmacy claims data. We also reviewed extant 
measures cataloged in the National Quality Measures 
Clearinghouse, developed by the US Agency for Health-
care Research and Quality (AHRQ). Additional candi-
date measures were brainstormed by the research team, 
drawing from their experience in pharmacoepidemiologic 
research (e.g., awareness of relevant US Food and Drug 
Administration alerts and clinical practice guidelines). 
Our measure review was limited to US sources. The 
candidate measures identified through these steps were 
then reviewed by three clinical geriatric pharmacother-
apy experts who rated the dimensions of each candidate 
measure as “Yes,” “No,” or “Uncertain” according to (1) 
feasibility of adaptation to pharmacy claims data, (2) 
whether the measure was evidence-based, and (3) whether 
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the measure was applicable to older adults. From the 42 
candidate measures identified, 19 were selected by all 
reviewers as a “Yes” for all three of these dimensions. 
These spanned the domains of safety (n = 7), effectiveness 
(n = 7), and efficiency (n = 5) (Table S1 in the Electronic 
supplementary material, ESM). The measures were con-
figured so that a score of 100% indicated optimal perfor-
mance. For example, for a safety measure about avoid-
ing the chronic use of benzodiazepines, we determined 
the proportion of older adults without ≥ 60 days’ supply 
of benzodiazepines during a measurement year, where 
100% indicated optimal performance for that measure. 
Additionally, the observations within each domain were 
aggregated to determine an overall average score repre-
senting the total number of opportunities to avoid a qual-
ity problem for each domain.
The measures were operationally defined by the project 
team and pilot tested using pharmacy data provided by a 
national pharmacy chain. This data source included all 
older adults (age 65 or older) residing in an East Coast 
state who received at least one medication dispensed by 
that pharmacy chain during 2016. Medication attributes 
were identified using National Drug Codes. Where rel-
evant, study eligibility criteria included the requirement 
that patients had received at least one dispensing of any 
medication within the first and last quarters of the meas-
urement year. This criterion was intended to increase the 
likelihood that the study patients continued to receive 
their medication from the same pharmacy system that 
provided the data. Measure numerators and denomina-
tors and associated specifications were defined in a nar-
rative document which guided the development of the 
analysis plan.
We excluded patients who received cancer medications, 
as many of our measures were not intended for end-of-life 
care. Patient demographics included age, gender, region of 
the state from which the prescription was dispensed, and 
payment type. We also identified the top five medical pro-
vider groups in the state by patient population, and attrib-
uted patients to these groups using a deidentified National 
Provider Identifier code. These groups represented lead-
ing medical practice organizations within the state. For 
the variables defining region, payment type, and provider 
group, the most frequent observation was used.
Descriptive statistics included patient age, gender, 
region, and payment type. Confidence intervals for 
the measures were derived from the standard error and 
denominator size. We performed a multivariable logistic 
regression analysis for each measure to determine if results 
differed significantly according to covariates. Statistical 
analyses were conducted using the software SAS 9.4 (SAS 
Institute Inc., Cary, North Carolina).
3  Results
3.1  Quality Measures
Detailed specifications of the S–E–E measures are 
included in Table  S1 of the ESM. Seven measures 
addressed medication safety—avoiding the chronic use of 
benzodiazepines or central nervous system (CNS) depres-
sants, avoiding the concurrent use of nonsteroidal anti-
inflammatory medications (NSAIDS) and anticoagulants, 
avoiding the concurrent use of anticholinergic medications 
with anti-dementia medications, avoiding the use of fluo-
roquinolones as initial therapy, avoiding the chronic use 
of opioids after the initial opioid prescription, and avoid-
ing selected high-risk medications. The high-risk medica-
tions included a condensed version of medications listed 
in the Beers and the Healthcare Effectiveness Data and 
Information Set criteria, deemed by our team to repre-
sent medications that present higher risk than therapeutic 
alternatives (e.g., first-generation antihistamines, tertiary 
tricyclic antidepressants; see Table S2 of the ESM for a 
complete listing).
The domain of effectiveness included five measures 
addressing patient adherence and two measures address-
ing the use of evidence-based medications in diabetes. One 
additional measure was tested that addressed the prioritiza-
tion of recommended medications for hypertension: avoid-
ing alpha- and beta-adrenergic blockers in the absence of 
compelling comorbidities. This measure was eventually 
abandoned due to its complexity. The effectiveness meas-
ures of patient adherence addressed the following chronic 
therapies: direct oral anticoagulant (DOAC) medications, 
oral antidiabetic medications, antidepressants, statins, and 
maintenance respiratory inhalers. Adherence was speci-
fied using a medication possession ratio (MPR) approach. 
We considered patients to be adherent if MPR was 0.8 
or higher, indicating that the patient had medication sup-
plied for at least 80% of the days between the first pre-
scription of the relevant medication and the last day of 
the measurement year. A MPR of 0.8 or higher is a widely 
used threshold of medication adherence [9]. The measures 
of evidence-based medication use in diabetes identified 
patients who received at least one dispensing for an oral 
or injectable diabetes medication during 2016. Among this 
group, we identified the proportion who also received at 
least one dispensing for (1) a statin medication and (2) an 
angiotensin-acting medication.
The measures within the domain of efficiency addressed 
health system use and the utilization of generic medications. 
The former included measures determining the patient’s total 
number of prescribers and the total number of medications 
prescribed. We set a threshold of five or more prescribers 
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as indicating a higher risk of medication-related problems 
associated with care fragmentation, and the patient’s receipt 
of an average of ten or more medications per month as a 
somewhat arbitrary threshold for a patient receiving a sub-
stantial number of medications which might trigger the need 
for regimen review. We also included measures of generic 
medication use, measured as an overall generic utilization 
rate, and including generic utilization rates for medications 
for diabetes and depression. Most US states either mandate 
or permit the substitution of generic formulations, yet oppor-
tunities may exist to increase the use of lower cost generics 
as alternatives to newer and higher-priced brand-name medi-
cations within the same therapeutic class when clinically 
appropriate.
3.2  Quality Measures in the Patient Population
The measures were applied to the eligible older population 
(N = 99,056). A majority of the patients were aged > 70 years 
(60.5%), female (56.5%), and had public insurance (Medicare) 
identified as the primary payment type (75.9%) (Table 1).
Results indicated a range of opportunities to improve 
medication use among older adults (Fig. 1). For the domain 
of safety, 12.8% of patients received a benzodiazepine chron-
ically, while 23.6% received chronic CNS depressant medi-
cation. Additionally, among all new antibiotic prescriptions 
(no previous antibiotic prescription in the previous 60 days), 
fluoroquinolones represented 16.7% of dispensings. The 
safety measure addressing opioid use determined the number 
of patients with at least one opioid prescription who received 
at least 200 opioid dosage units, and 21.9% were found to 
have received at least this amount.
Within the domain of effectiveness, 71.7% of patients 
were adherent to DOAC, 82.8% to antidiabetic medications, 
76.3% to antidepressants, 80.4% to cholesterol medications, 
and 46.1% to chronic respiratory inhalers. Approximately 
three of four patients with medications for diabetes also 
received at least one dispensing of a statin (74.4%) and at 
least one dispensing of an angiotensin-acting medication 
(73.6%). For the domain of efficiency, 78.3% of patients 
received prescriptions from less than five unique prescrib-
ers, and 93.3% utilized less than an average of ten medica-
tions per month. Additionally, among all of the dispensings 
that occurred in 2016, 87.4% were for generic medications, 
88.7% of the dispensings for antidiabetic medications were 
for generics, while 98.7% of the dispensings for antidepres-
sants were for generic products.
The aggregated results indicated that, overall, 85.7%, 
76.1%, and 87.9% of the study population showed safe, 
effective, and efficient prescription medication use, respec-
tively (Fig. 1).
3.3  Predictors of Optimal Performance
3.3.1  Safety
Measure rates were generally similar regardless of patient 
age group and gender, although some significant differ-
ences were identified. Compared to older adults aged 
65–70 years, those  who were > 80 years old had signifi-
cantly higher odds of avoiding benzodiazepines [adjusted 
odds ratio (AOR) = 1.21, 95% confidence interval (CI) 
1.13–1.29] and avoiding the use of CNS depressant agents 
(AOR = 1.21, 95% CI 1.15–1.28) (Table 2). Older adults 
aged > 80 years with dementia were almost twice as 
likely to avoid anticholinergics compared with those aged 
65–70 years (AOR = 1.98, 95% CI 1.05–3.72). Additionally, 
patients above 70 years of age were significantly more likely 
to avoid current NSAIDs and anticoagulants (AORs were 
1.45 and 2.17 for the 71–80 years group and those above 
80 years of age, respectively), and also more likely to avoid 
high risk medications. Older adults aged > 70 years were 
significantly less likely to avoid receiving fluoroquinolones 
as initial therapy compared to those 65–70 years of age 
(AOR = 0.79). Compared to males, females were signifi-
cantly less likely to avoid benzodiazepines (AOR = 0.55) 
or CNS depressants (AOR = 0.68), fluoroquinolones as ini-
tial therapy (AOR = 0.81), or opioids in larger quantities 
(AOR = 0.83).
Table 1  Study population: 
community-dwelling older 
adults from an east coast state 
who filled prescriptions in 2016 
(N = 99,056)





















177Quality Measures of Drug Use in Elderly
3.3.2  Effectiveness
Compared to older adults aged 65–70 years, those aged 
71–80 years were significantly more likely to adhere to 
oral antidiabetic (AOR = 1.16, 95% CI 1.02–1.32) and 
cholesterol (AOR = 1.08, 95% CI 1.02–1.16) medications, 
and those aged > 80 years were more likely to adhere to 
cholesterol medications (AOR = 1.18, 95% CI 1.10–1.28) 
(Table 3). Among patients with diabetes, those in the 
71–80 years age group were significantly more likely to 
receive a prescription of a statin (AOR = 1.16) compared 
to those aged 65–70 years. However, those above 80 years 
of age were significantly less likely to receive a prescrip-
tion for a statin (AOR = 0.86, 95% CI 0.77–0.99) or an 
ACEI/ARB (AOR = 0.79, 95% CI 0.71–0.89). Females 
were significantly less likely to adhere to cholesterol medi-
cations than males (AOR = 0.89, 95% CI 0.84–0.95).
3.3.3  Efficiency
Compared to older adults aged 65–70 years, those aged 
> 70 years were significantly less likely to have fewer (≤ 5) 
prescribers (AORs were 0.82 and 0.92 for the 71–80 years 
group and for those above 80 years, respectively) (Table 4). 
Additionally, females were significantly less likely to avoid 
receiving at least ten medications than males (AOR = 0.84, 
95% CI 0.76–0.94).
4  Discussion
Given the ubiquity of medication use among older adults 
and its substantial potential for both benefit and harm, 
assessing the quality of medication use is vital to optimize 
patient health outcomes. At the provider level, this task is 
Fig. 1  Overall results for the 
S–E–E quality measurement 
framework addressing safety, 
effectiveness, and efficiency of 
medication use among older 
adults
Safe (S) Effective (E) Efficient (C)
Overall Results: 85.7% Overall Results: 76.1% Overall Results: 87.9% 
Avoid use of:
S1.  Benzodiazepines 
S2.  CNS depressants 
S3.  NSAIDS, if using 
anticoagulants 
S4.  Anticholinergics in dementia 
S5.  Fluoroquinolones as initial 
therapy 
S6.  Chronic opioids  
S7.  High-risk / potentially 
inappropriate drugs 
Patient adherence to:
E1.  Direct anticoagulants  
E2.  Diabetes medications 
E3.  Depression medications 
E4.  Cholesterol medications 
E5.  Respiratory inhalers 
Evidence-based therapies:
E6.  Statin use in diabetes 
E7.  ACEI/ARB use in diabetes 
Health system use:
C1.  Limit number of 
prescribers 
C2.  Avoid use of 10 or more 
medications in a month  
Use of generics:  
C3.  Overall 
C4.  Diabetes medications 
C5.  Antidepressants 
CNS=Central Nervous System; ACEI=Angiotensin Converting Enzyme Inhibitors; ARB=Angiotensin II Receptor Antagonists; 
NSAIDs=Non-Steroidal Anti-Inflammatory Drugs 
87.2%
76.4%
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Table 2  Adjusted odds of desired performance for medication safety quality measures, shown as odds ratio (95% confidence interval)
Adjusted for provider group
ref reference, CNS central nervous system, NSAIDs nonsteroidal anti-inflammatory drugs
P < 0.05 for values in bold
S1. Avoid ben-
zodiazepines


















































































































Table 3  Adjusted odds of desired performance for medication effectiveness quality measures, shown as odds ratio (95% confidence interval)
Adjusted for provider groups
ref reference, ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin II receptor antagonists
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complicated by a fragmented health care system and often a 
lack of physician constancy. Population-level approaches to 
evaluate the quality of medication use among older adults 
are needed. Although several leading entities incorporate 
prescription medication use measures into their quality 
improvement efforts, evaluating and improving medication 
use among older adults remains a formidable challenge. In 
our comprehensive population-level study of the use of pre-
scription medications among older adults, we found con-
siderable room for improvement, with deficits from optimal 
performance ranging from 12.1% for the domain of effi-
ciency, 14.3% for the domain of safety, and 23.9% for the 
domain of effectiveness.
Several measures stood out in terms of opportunity for 
improvement. Within the domain of safety, almost one-fourth 
of the study population (76.4%) received at least 60 days’ 
supply of CNS depressant medication. Bernardy et al. found 
that 12% of older veterans with post-traumatic stress dis-
order concurrently received three or more classes of CNS 
depressants [10]. Additionally, we found that women were 
less likely than males to avoid CNS depressants, a finding 
consistent with that reported by Bernardy et al. [10]. Given 
the increased risk of cognitive decline and falls associated 
with the use of CNS depressants in older adults [11], our 
finding raises concerns about increased potential adverse 
events among these patients. We considered it important to 
include a measure of opioid utilization in the safety domain. 
This measure reflects the ratio of short-term to chronic opioid 
utilizers, consistent with the aim that if opioids are pre-
scribed, they should be used as briefly as possible and at the 
lowest dosage possible [12]. Furthermore, 13% of the study 
population were prescribed benzodiazepines chronically, a 
finding generally consistent with that reported in US-based 
studies [13–15]. A study conducted among older Medicare 
enrollees entering home healthcare services reported that 
19% were prescribed a benzodiazepine [13], while another 
study reported that the prevalence of benzodiazepine use was 
approximately 10% among older veterans [14]. Yet another 
study by Maust et al. found that 13% of older adults reported 
using benzodiazepines [15]. Our result was substantially 
lower than the percentages reported by non-US studies [16, 
17]: a Canadian study found that 25% of community-dwelling 
older adults used benzodiazepines [16], while a Brazilian 
study reported that the prevalence of benzodiazepine use 
among older adults was 21–27% [17]. Our finding is poten-
tially alarming given the risks of these medications, which 
include cognitive impairment, delirium, falls, and fractures 
[18], leading to the recommendation that benzodiazepines 
should be avoided in this vulnerable population [6]. Our find-
ing that females were less likely to avoid benzodiazepine use 
is consistent with an earlier report [19], indicating that efforts 
to reduce benzodiazepine use in this subgroup are needed.
For the domain of effectiveness, the measures of medi-
cation adherence indicated that a substantial percentage of 
patients do not refill prescriptions regularly. The lowest rate 
was among patients utilizing chronic inhalers for respiratory 
disease. Poor consistency in the refilling of chronic inhalers 
among older adults has been reported previously [20, 21]. 
Our finding may also suggest that some patients did not have 
chronic respiratory illness and were prescribed the inhaler 
on a short-term basis. Adherence to DOAC medication was 
71.7%, a finding consistent with that reported in a published 
study [22]. A slightly higher percentage (76.3%) of the 
patients were adherent to antidepressant medications. Plac-
ing this result in the context of the literature on adherence 
with antidepressants is complicated by the predominance of 
research that focuses on treatment persistence in new therapy 
initiators only. Such research excludes the majority of patients 
who utilize antidepressant medications chronically, and while 
these medications may not need to be taken indefinitely, they 
should not be taken sporadically, as poor adherence patterns 
reveal. We believe that reporting adherence rates among all 
patients prescribed antidepressants, not just new therapy initi-
ators, is a better approach. Approximately 80% of the patients 
were adherent to antidiabetic medications and cholesterol 
medications, underscoring the continuing need to promote 
adherence to these vital therapies. In addition, the finding that 
approximately one in four patients receiving medication for 
diabetes did not also receive a statin or an angiotensin-acting 
medication justifies the continued emphasis on these impor-
tant elements of diabetes care [23–25].
Table 4  Adjusted odds of desired performance for medication effi-
ciency quality measures, shown as odds ratio (95% confidence inter-
val)
Adjusted for provider groups
Results of regression analyses are not reported for measures C3-C5 
that address the utilization of generic medications (overall rate, and 
for diabetes and mental health medications) because provider groups 
and regions varied with prescription
ref reference
P < 0.05 for values in bold




 71–80 years 0.82 (0.78–0.86) 0.90 (0.80–1.01)
 81+ years 0.92 (0.87–0.97) 1.10 (0.96–1.27)
Gender (ref = male)
 Female 0.97 (0.93–1.01) 0.84 (0.76–0.94)
Region (ref = A)
 B 1.01 (0.93–1.10) 0.85 (0.71–1.03)
 C 0.96 (0.91–1.02) 1.09 (0.95–1.25)
 D 0.81 (0.76–0.87) 1.24 (1.02–1.52)
 E 0.91 (0.86–0.97) 1.33 (1.12–1.58)
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For the domain of efficiency, we found that 21.7% of 
patients filled prescriptions from five or more unique pre-
scribers. Having multiple prescribers has been shown to 
increase the risk of adverse drug events [26] and is associ-
ated with unnecessary medication use in older adults [27]. 
Our measure of receiving an average of ten or more medica-
tions per month may be considered extreme, as others have 
defined polypharmacy as five concurrent medications [28]. 
Yet, rather than classify a large proportion of patients as 
receiving a substantial number of medications, our higher 
threshold of at least ten prescribed medications identifies 
a smaller percentage of patients (6.7%) who would be at a 
higher risk for adverse drug events and associated health 
care costs. Measures addressing the utilization of generics 
revealed a limited opportunity for improvement. The overall 
generic utilization rate of 87.4% indicates that a substantial 
proportion of the medications utilized by older adults were 
not higher-cost branded products.
In our study, we offer a novel approach to the comprehen-
sive assessment of medication use among older adults, which 
can augment other efforts to address quality of medication 
use in this population. The Beers criteria is well recognized 
as an important guide for prescribers, yet the medications it 
includes represent only a portion of all commonly prescribed 
medications that have the potential for untoward effects, 
while medication cost is beyond its scope [29–31]. The MAI 
does not directly address adherence patterns or cost using 
claims data [32]. Another notable framework, the START/
STOPP criteria [33], contains a comprehensive validated 
array of standards that address inappropriate medication use 
and underuse. The START/STOPP criteria are intended for 
application in clinical settings, rather than for population-level 
analysis using administrative data sources. Many of the qual-
ity measures in the ACOVE project address medication use, 
yet the measures that can be calculated using administrative 
data require medical diagnoses beyond what is available in 
pharmacy data. Lastly, the PQA [3] has developed measures 
within the domains of adherence, appropriate medication use, 
safety, medication therapy management, and quality improve-
ment, and many of their measures address similar dimensions 
of medication use to those in our framework. However, we 
sought to include only measures that can be reported using 
pharmacy claims solely, that address medication use among 
older adults exclusively, and can be aggregated to provide a 
profile score for each domain of medication use.
Several limitations of our study are important to note. Our 
review of relevant measures was restricted to the US; we did 
not review relevant quality measures or initiatives from other 
nations. We also note that the measures described here should 
not be interpreted as explicit criteria. Clinical circumstances 
can warrant, for example, the chronic use of benzodiaz-
epines or the need for large quantities of opioid medications. 
For instance, among several factors, comorbidities, disease 
severity, physical function, and frailty may affect the quality 
of medication use in older adults. Thus, our measures should 
only be applied at larger units of analysis and to identify 
substantial differences across groups of similar patient popu-
lations. Also, measures described here are not universally 
accepted criteria. However, we describe a comprehensive 
framework that can be applied using prescription medication 
pharmacy claims and can examine the quality of prescrip-
tion medication use in older adults. Additionally, pharmacy 
claims data are limited by a lack of information about patient 
diagnoses, disease severity, race/ethnicity, household income, 
and education, so these factors could not be assessed. Also, 
the findings may not be generalized to older adults from a 
different US region or pharmacy retailer. Finally, we did not 
formally evaluate the reliability and validity of the measures 
described in this study. An important next phase of this study 
is to determine if patient health outcomes differ according to 
the results for each domain. Further validation is warranted 
before the wide-scale application of this measurement frame-
work for the purpose of accountability.
5  Conclusion
We provide a novel method to comprehensively evaluate 
quality of medication use among older adults using real-
world prescription claims data. We found that a majority 
of older adults received safe, effective, and efficient pre-
scription medications. However, our results also revealed 
a range of opportunities within each domain to better align 
medication use with current recommendations. Future 
studies are required to ascertain the validity of the meas-
ure set considering adverse events, health outcomes, and 
healthcare utilization.
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